1. Accueil
  2. Chemobiologie et Pharmacognosie pour la Santé (CPS)
  3. Groupe Bonnet
  4. Brevets

Brevets

Patents and licensed patents since 2001

  • Fluorogenic Dimer compound, useful as a probe for detection of endogenous receptors
    Karpenko I.; Collot M.; Klymchenko A.; Bonnet D.
    EP20305479.6, 12-05-2020
    Licence d’exploitation accordée à la Société Domain Therapeutics (2021)

  • Pyrimidinone derivatives and uses thereof to neutralize the biological activity of chemokines
    Bonnet D.; Frossard N.; Galzi JL; Hibert M.; Muller S.; Guignabert C.; Simonin F.
    EP16305908, 13-07-2016; WO2018011376, 18-01-2018

  • Metabolically stable spexin peptide analogs
    Esteoulle L.; Simonin F.; Bonnet D.
    EP16305734.2, 16-06-2016; WO2017216360; 21-12-2017

  • Metabolically stable peptide analogs
    Iturrioz X.; Llorens-Cortes C.; Bonnet D.
    EP16305733.4, 16-06-2016 ; WO2017216359; 21-12-2017

  • Pyrimidinone derivatives and uses thereof to neutralize the biological activity of chemokines
    Bonnet D.; Frossard N.; Galzi JL; Hibert M.; Muller S.; Guignabert C.; Simonin F.
    EP16305908, 13-07-16

  • Metabolically stable spexin peptide analogs
    Esteoulle L.; Simonin F.; Bonnet D.
    EP16305734.2, 16-06-2016.

  • Metabolically stable peptide analogs
    Iturrioz X.; Llorens-Cortes C.; Bonnet D.
    EP16305733.4, 16-06-2016

  • Metabolically stable apelin analogs in the treatment of disease mediated by the apelin receptor.
    Iturrioz, X.; Llorens-Cortes, C.; Bonnet D.
    WO2016/102648, 30-06-2016

  • Bisacodyl and analogues as drugs for treating cancer.
    Feve M, Zeniou M, Haiech J, Chneiweiss H, Kilhoffer M-C, Mameri S, Hibert M
    WO 2012/168885 A2

  • Labeled ligands of the oxytocin receptor.
    Bonnet D, Hibert M, Durroux T, Pflimlin E
    FR12 306 226.7, 08-10-2012; PCT/EP2013/070837, 7-10-2013.

  • Dérivés de la 2,3,4,5-tétrahydro-1H-benzo[b]azépine et leur utilisation.
    Bonnet, D.; Hibert, M.; Loison, S.; Mouillac, B.; Durroux, T.
    FR1061322, 28-12-2010

  • Novel compounds which interact with PEA-15.
    Renault F, Chabane H, Bonnet D, Hibert M, Haiech J,  Chneiweiss H.
    WO2007071874 (16/08/2007).

  • Nouveaux composés interagissant avec PEA-15
    Renault F, Chabane H, Bonnet D, Hibert M, Haiech J, Chneiweiss H.
    FR2894963 (22/06/2007).

  • Method for binding, in solution, a peptide and a lipophilic vector and uses thereof
    Bonnet, D.; Bourel, L.; Melnyk, O.;  Gras-Masse, H.
    FR2813794, 15-03-2002; US2004092015, 13-05-2004; WO0220558 A3, 09-01-2003.

  • Use of mixtures of lipopeptides for vaccine production.
    Guillet, J.-G.; Bourgault-Villada, I.; Dupuis, M.; Gras Masse, H.; Bourel, L.; Melnyk, O.; Joly, P.; Bonnet, D.; Malingue, F.; Grandjean, C.; Georges, B.
    FR2837104, 19-09-2003; WO03075956, 08-04-2004

  • Use of N,N',N'-tri(t-butoxycarbonyl)hydrazine-N-acetic acid or N,N'-di(t-butoxycarbonyl)hydrazine-N-acetic acid for functionalizing a peptide with a hydrazinoacetyl group
    Bonnet, D.; Melnyk, O.; Gras-Masse, H.
    FR2797632, 23-02-2001

  • Method for coupling, in solution, a peptide with at least another compound and uses thereof
    Bonnet, D.; Melnyk, O.; Gras-Masse, H.
    WO0114408, 30-08-2001.

  • Coupling a peptide to a nonpeptide compound having a carboxy or hydroxy functional group comprises forming a hydrazide linkage
    Bonnet, D.; Melnyk, O.; Gras-Masse, H.
    FR2797631, 23-02-2001.

Licensed patents

Bürkert

  1.  Fluorescent Dyes and Dye Precursors
    Lelant C.; Bonnet D.; Galzi JL.
    EP15153463, 02-02-2015


Transition Therapeutics (Phase 2)

  1. Anti-inflammatory and protein kinase inhibitor composition and method of use
    D. Watterson, L. Van Eldik, A. Velentza, M. Zasadzki, A. Sawkar, T. Lukas, S. Mizoeva, J. Haiech, M. Hibert, J.J. Bourguignon
    WO03018563, 6 mars 2003.
  2. Anti-inflammatory and protein kinase inhibitor compositions and related methods for downregulation of detrimental cellular responses and inhibition of cell death
    D. Watterson, A. Sawkar, T. Lukas, S. Mirzoeva, L. Van Eldik, M. Hibert, A. Velentza, M. Zasadzki, J. Haiech, J.J. Bourguignon
    US2003176437, 18 septembre 2003.

Domain Therapeutics

  1. Method for isolating an allosteric effector of a receptor.
    J.L. Galzi, M. Hibert, J.J. Bourguignon, E. Maillet
    FR2840993, WO03107004, 24 décembre 2003
  2. Collections de composes traçables et leurs utilisations
    F. Pattus, F. Guillier, M. Hibert, C. Franchet, J.L. Galzi
    FR2871464, 16 décembre 2005
  3. Collections de composes traçables et leurs utilisations
    F. Pattus, F. Guillier, M. Hibert, C. Franchet, J.L. Galzi
    FR2871465, 16 décembre 2005
  4. Collections of traceable compounds and uses thereof
    M. Hibert, C. Franchet, J.L. Galzi, F. Pattus, F. Guillier
    WO2006003329, 12 janvier 2006.
  5. Collections of traceable compounds and uses thereof
    M. Hibert, C. Franchet, J.L. Galzi, F. Pattus, F. Guillier
    WO2006003330, 12 janvier 2006.

 Immune Targeting System Ltd (Flunisyn™, phase IIb)

  1. Vaccines comprising fluorocarbon vector and antigenic epitopes for cell targeting and immunotherapy of infection, autoimmune disease and cancer.
    Bonnet, D.; Brown, C. B.; Georges, B.; Sizer, P. J.
    GB0408164D, 05-19-2004.
  2. Antigen Delivery Vectors and Constructs
    Bonnet, D.; Brown, C. B.; Georges, B.; Sizer, P. J.
    WO2005099752, 02-02-2006.
  3. Influenza antigen fluorocarbon vectors and constructs.
    Bonnet, D.; Brown, C. B.; Georges, B.; Sizer, P. J.
    US 2009191233 , 30-07-2009
  4. Influenza antigen delivery vectors and constructs.
    Bonnet D.; Brown C. B.; Bertrand G.; Sizer P.J.
    WO2009027688, 05-03-2009; SI1740207, 30-04-2013; TW2013/45551, 16-10-2013.